Medscape (9/9, Davenport, Subscription Publication) reports, “Patients who have major depressive disorder (MDD) and who are at imminent risk for suicide may experience rapid benefit from esketamine nasal spray (Spravato, Janssen Pharmaceuticals) used in conjunction with the standard of the care,” research indicated. Specifically, “in the phase 3 Aspire I and Aspire II trials, more than 450 patients who had MDD and were at risk for suicide were randomly assigned to receive esketamine…or placebo,” and “both groups also received comprehensive standard of care that included antidepressants.” The findings were presented at the 32nd European College of Neuropsychopharmacology Congress.
Related Links:
— Medscape (requires login and subscription)